Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
āļĢāļąāļāļāļēāļĨāļŠāļŦāļĢāļąāļāļŊ āļāļģāļĨāļąāļāļĄāļāļāļŦāļēāļŠāļąāļāļŠāđāļ§āļāļāļēāļĢāļāļ·āļāļŦāļļāđāļāđāļāļĒāļļāļ AI āļŦāļĢāļ·āļāđāļĄāđ? āļ§āļāļāļīāļāļāļąāļāļāļļāļāļāļĢāļ°āđāļāđāļāļāļāđāļāļĩāļĒāļāļāļĢāļąāđāļāđāļŦāļĄāđ!
āļāđāļēāļ§āđāļāđāļāļ§āļąāļāļāļĩāđ 5 āļĄāļī.āļĒ.
EU Wrap: āļāļĨāļēāļāļĒāļąāļāļāļāļāļĢāļāļāļąāļ§ āļāđāļēāļĄāļāļĨāļēāļāļāļēāļĢāļŠāļĨāļąāļāļāļĨāļļāđāļĄāļŦāļļāđāļ ð
Broadcom āļāļģāļāļĨāļāļĢāļ°āļāļāļāļāļēāļĢāļāļĩāļāļ§āđāļēāļāļēāļ āđāļāđāļĢāļēāļāļēāļŦāļļāđāļāļĢāđāļ§āļāđāļāļ·āļāļ 13% âïļ
